ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
ARET2121: Intravitreal Melphalan for Intraocular Retinoblastoma
Protocol ID
ARET2121
Disease (Sub Disease)
Bilateral Retinoblastoma
Childhood Intraocular Retinoblastoma
Group D Retinoblastoma
Stage I Retinoblastoma
Unilateral Retinoblastoma
Diagnosis Stage
Newly diagnosed
Location
WA
Sponsor
Children's Oncology Group
Links
External Registry ≫
Trial Status
Open
Sites
Perth Children's Hospital
Study Type
Treatment
Phase
Phase 2
Age Eligibility
up to 18 Years
International registry ID's
NCT05504291
Back to Registry
Study Title ARET2121: Intravitreal Melphalan for Intraocular Retinoblastoma
Protocol ID ARET2121
Disease (Sub Disease) Bilateral Retinoblastoma
Childhood Intraocular Retinoblastoma
Group D Retinoblastoma
Stage I Retinoblastoma
Unilateral Retinoblastoma
Diagnosis Stage Newly diagnosed
Location WA
Sponsor Children's Oncology Group
Links https://clinicaltrials.gov/ct2/show/NCT05504291
Trial Status Open
Sites Perth Children's Hospital
Study Type Treatment
Phase Phase 2
Age Eligibility up to 18 Years
International registry ID's NCT05504291

Join our newsletter

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Email info@anzchog.org   |  

Level 6, TRF Building, Hudson Institute, 27-31 Wright St, Clayton VIC 3168

ANZCHOG acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait Islander cultures, and to Elders both past and present. We acknowledge Māori as tangata whenua of Aotearoa New Zealand and as Treaty partners with the Crown as agreed in Te Tiriti o Waitangi. 

We are committed to creating a safe and welcoming environment that embraces all backgrounds, cultures, sexualities, genders and abilities.